sirolimus

Type: Keyphrase
Name: sirolimus
First reported 16 hours ago - Updated 15 hours ago - 1 reports

New Findings on Macrolides from University of Barcelona Summarized (Distinct deleterious effects of cyclosporine and tacrolimus and combined...

New Findings on Macrolides from University of Barcelona Summarized (Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide)By a News Reporter-Staff News Editor ... [Published HispanicBusiness.com - 16 hours ago]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Application note for sample preparation for immunosuppressants using the MassSTAR

together with its partner Chromsystems released an application note about immunosuppressant monitoring using the MassSTAR with Chromsystems’ CE-IVD Mass-Tox® Immunosuppressants kit and corresponding CE-IVD protocol.The application note shows that completely ... [Published MyNewsDesk - Jul 30 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

[Comment] Alemtuzumab induction therapy in kidney transplantation

In The Lancet, Peter Friend and the 3C Study Collaborative Group report the results of the first part of the 3C Study—an open-label, randomised, multicentre study of alemtuzumab compared with basiliximab induction treatment, followed by sirolimus versus ... [Published The Lancet online - Jul 28 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 3 reports

Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome

— NEJM This article is available to subscribers.Sign in now if you're a subscriber. BackgroundAlthough thrombosis is considered the cardinal feature of the antiphospholipid syndrome, chronic vascular lesions are common, particularly ... [Published New England Journal of Medicine - Jul 24 2014]
Entities: sirolimus, Paris, Antibody
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Newer DES Up Survival vs Meds Only in Stable CAD: Analysis

BERN, SWITZERLAND — A new meta-analysis adds some wrinkles to already-complex issues regarding best treatment options for patients with stable CAD [1] . It suggests that medical therapy plus revascularization with PCI using "newer-generation" drug-eluting ... [Published American Journal of Public Health - Jul 18 2014]
First reported Jul 16 2014 - Updated Jul 17 2014 - 2 reports

First patient enrollment in MASCOT registry represents major milestone for COMBO™ Dual Therapy Stent …

/PRNewswire/ -- OrbusNeich today announced that the first patient has been enrolled in theMultinational Abluminal Sirolimus Coated BiO-Engineered StenT (MASCOT) post-marketing registry. The first COMBO™ Dual Therapy Stent implant was performed at the ... [Published Yahoo! Finance - Jul 16 2014]
First reported Jul 15 2014 - Updated Jul 16 2014 - 2 reports

Extraction d'immunosupresseurs sur le Hamilton Microlab MassStar

together with its partner Chromsystems released an app note about immunosuppressant monitoring using the MassSTAR with Chromsystems’ CE-IVD Mass-Tox® Immunosuppressants kit and corresponding CE-IVD protocol.The application note shows that completely automated ... [Published MyNewsDesk - Jul 16 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

New Option to Prevent Graft-vs-Host Disease

Prophylaxis with tacrolimus/sirolimus provided equivalent graft-vs-host disease (GVHD)-free survival in patients undergoing matched, related donor hematopoietic cell transplantation compared with tacrolimus/methotrexate, according to results of a study ... [Published Cancernetwork.com - Jul 15 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

For Steroid-Resistant Autoimmune Hepatitis, Consider Sirolimus

Chatrath H, Allen L, Thomas D. Boyer TD. Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med (2014) Online June 27, 2014 doi: http://dx.doi.org/10.1016/j.amjmed.2014.06.016In this small series, sirolimus offered an additional ... [Published Consultant Live - Jul 10 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

"Bioabsorbable Medical Devices and Methods of Use Thereof" in Patent Application Approval Process

By a News Reporter-Staff News Editor at Drug Week -- A patent application by the inventors Milner, Keith R. ( West Lafayette, IN ); Carlson, James M. ( Lafayette, IN ); Charlebois, Steven ( West Lafayette, IN ); Gearhart, Krista N . ( Lafayette, IN ); ... [Published HispanicBusiness.com - Jul 10 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 2 reports

Micell Technologies Adds to Portfolio of Intellectual Property Protection

/PRNewswire/ --Micell Technologies, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to Micell's technology for enhancing the performance of medical devices with precise drug-delivery coatings. ... [Published FinanzNachrichten.de - Jul 09 2014]
First reported Jul 03 2014 - Updated Jul 04 2014 - 2 reports

Bone marrow transplantation shows potential for treating adults with severe sickle cell disease

Current ratings for: Ratings require JavaScript to be enabled.Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) with severe sickle cell disease, according to a study in JAMA .Myeloablative ... [Published Medical News Today - Jul 03 2014]

Quotes

...According to news reporting out of Barcelona, Spain , by NewsRx editors, research stated, "Endothelial dysfunction seems to be a key factor in the development of several complications observed early after hematopoietic stem cell transplantation (HSCT). The conditioning regimen and many other factors associated with the procedure are responsible for this endothelial damage."
...an important area of clinical investigation with stents, particularly the avoidance of neoatherosclerosis and late stent thrombosis," said Colombo. "The MASCOT registry will provide important information about the unique dual therapy approach of the Combo stent, which offers the possibility of functional arterial vessel healing, which we have not seen with any of the monotherapy drug-eluting stents."
"Our study suggests that a specific molecular pathway, the mTORC pathway, leads to intimal hyperplasia, which accompanies the most severe variants of the antiphospholipid syndrome" write Guillaume Canaud, MD, PhD, from the Institut Necker-Enfants Malades in Paris, France, and colleagues in an article published in the July 24 issue...
"Our results suggest that the mTORC pathway is involved in the vascular lesions associated with the antiphospholipid syndrome" the authors write

More Content

All (52) | News (42) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
New Findings on Macrolides from University of B... [Published HispanicBusiness.com - 16 hours ago]
First Patient Enrolled in MASCOT Registry for C... [Published Diagnostic & Invasive Cardiology - 21 hours ago]
Application note for sample preparation for imm... [Published MyNewsDesk - Jul 30 2014]
Stent Thrombosis and New-Generation DES in Prim... [Published General Medicine eJournal - Jul 28 2014]
[Comment] Alemtuzumab induction therapy in kidn... [Published The Lancet online - Jul 28 2014]
Inhibition of the mTORC Pathway in the Antiphos... [Published New England Journal of Medicine - Jul 24 2014]
Drug Target Linked to Antiphospholipid Syndrome [Published American Journal of Public Health - Jul 24 2014]
mTORC pathway involved in antiphospholipid sx v... [Published Medical Xpress - Jul 24 2014]
SUN PHARMA ADVANCED RESEARCH : Patent Issued fo... [Published 4 Traders - Jul 24 2014]
OrbusNeich enrolls first patient in coronary ar... [Published Individual.com - Jul 22 2014]
Newer DES Up Survival vs Meds Only in Stable CA... [Published American Journal of Public Health - Jul 18 2014]
Complications of Bariatric Surgery: Dumping Syn... [Published Pharmacy Times - Jul 17 2014]
Potential shown for possible bone marrow transp... [Published Irish Medical Times - Jul 16 2014]
Extraction d'immunosupresseurs sur le Hamilton ... [Published MyNewsDesk - Jul 16 2014]
First patient enrollment in MASCOT registry rep... [Published Yahoo! Finance - Jul 16 2014]
First Patient Enrolment in MASCOT Registry Repr... [Published OSIX News - Jul 16 2014]
Application note for sample preparation for imm... [Published MyNewsDesk - Jul 15 2014]
New Option to Prevent Graft-vs-Host Disease [Published Cancernetwork.com - Jul 15 2014]
New therapeutic combination to slow resistant s... [Published EurekAlert! - Jul 10 2014]
For Steroid-Resistant Autoimmune Hepatitis, Con... [Published Consultant Live - Jul 10 2014]
Early Stent Thrombosis in Patients With ACS [Published General Medicine eJournal - Jul 10 2014]
"Bioabsorbable Medical Devices and Methods of U... [Published HispanicBusiness.com - Jul 10 2014]
Micell Technologies Adds to Portfolio of Intell... [Published FinanzNachrichten.de - Jul 09 2014]
Micell Technologies Adds to Portfolio of Intell... [Published Industrial Info Financials - Jul 09 2014]
Bone marrow transplantation shows potential for... [Published Medical News Today - Jul 03 2014]
Low Intensity Bone Marrow Transplantation Looks... [Published MedIndia - Jul 03 2014]
Bone Marrow Transplant Feasible for Adults With... [Published Diabetes Care - Jul 01 2014]
Bone marrow transplantation shows potential for... [Published Medical Xpress - Jul 01 2014]
Activity of EGFR, mTOR and PI3K inhibitors in a... [Published 7thSpace - Jun 25 2014]
PCI With Newer Stents May Be as Safe as CABG in... [Published Diabetes Care - Jun 24 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
[Comment] Alemtuzumab induction therapy in kidn... [Published The Lancet online - Jul 28 2014]
In The Lancet, Peter Friend and the 3C Study Collaborative Group report the results of the first part of the 3C Study—an open-label, randomised, multicentre study of alemtuzumab compared with basiliximab induction treatment, followed by sirolimus versus ...
Svelte Medical Systems Announces Completion of ... [Published Venturebeat - May 29 2014]
SPONSORED POST Check out our  press release hub , powered by Business Wire. It's a one stop shop for industry announcements to help you stay on top of the latest technology and investment trends. Get the scoop  here . NEW PROVIDENCE, N.J.–(BUSINESS ...
AADi, Celgene ink licensing deal for nanotechno... [Published PBR - News - May 21 2014]
US-based clinical stage biopharmaceutical firm AADi has entered into an inlicensing agreement with Celgene for ABI-009, a nanoparticle albumin-bound (nab) version of the mTOR inhibitor sirolimus or rapamycin. ...
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - May 13 2014]
Santen Phase III Study Meets Primary Endpoint f... [Published Business Wire Health News - Apr 04 2014]
EMERYVILLE, Calif.--(BUSINESS WIRE)--Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the ...
1 2

Press Releases

sort by: Date | Relevance
Artikel im American Journal of Cardiology zeigt... [Published PR Newswire - Nov 21 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.